{"name":"Shionogi & Co.","slug":"shionogi","ticker":"4507.T","exchange":"TSE","domain":"shionogi.com","description":"Shionogi & Company, Limited  is a Japanese pharmaceutical company best known for developing Crestor. Medical supply and brand name also uses katakana (シオノギ).","hq":"Osaka, Japan","founded":1949,"employees":"~4,955","ceo":"Isao Teshirogi","sector":"Anti-Infectives / HIV / CNS","stockPrice":3076,"stockChange":98,"stockChangePercent":3.29,"marketCap":"$16.5B","metrics":{"revenue":3159193565.611452,"revenueGrowth":32.8,"grossMargin":83.5,"rdSpend":0,"netIncome":1297111949.2025025,"cash":4497787284.872875,"dividendYield":2.55,"peRatio":15.3,"fiscalYear":"FY2026"},"revenueBreakdown":[{"name":"Xocova","genericName":"ENSITRELVIR","slug":"ensitrelvir","revenue":400000000,"yoyGrowth":0,"percentOfTotal":57.1},{"name":"Fetroja","genericName":"CEFIDEROCOL","slug":"cefiderocol","revenue":300000000,"yoyGrowth":0,"percentOfTotal":42.9}],"timeline":[{"date":"1961-01-01","label":"Cuvposa first approved","drug":"Cuvposa","drugSlug":"glycopyrronium-bromide","type":"approval","sentiment":"positive"},{"date":"1971-01-01","label":"Keflex first approved","drug":"Keflex","drugSlug":"cefalexin","type":"approval","sentiment":"positive"},{"date":"2007-01-01","label":"Doribax first approved","drug":"Doribax","drugSlug":"doripenem","type":"approval","sentiment":"positive"},{"date":"2009-01-01","label":"Ulesfia first approved","drug":"Ulesfia","drugSlug":"benzyl-alcohol","type":"approval","sentiment":"positive"},{"date":"2019-01-01","label":"Fetroja first approved","drug":"Fetroja","drugSlug":"cefiderocol","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-06-01","label":"Ospemifene patent cliff ($1.2B at risk)","drug":"Ospemifene","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Respiratory","slug":"respiratory","revenue":400000000,"percentOfTotal":57.1,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Xocova","genericName":"ENSITRELVIR","slug":"ensitrelvir","indication":"Disease caused by Severe acute respiratory syndrome coronavirus 2","status":"marketed","revenue":400000000},{"name":"Oral Glycopyrrolate Liquid","genericName":"Oral Glycopyrrolate Liquid","slug":"oral-glycopyrrolate-liquid","indication":"Chronic obstructive pulmonary disease (COPD)","status":"phase_3"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":300000000,"percentOfTotal":42.9,"drugCount":3,"colorKey":"immunology","drugs":[{"name":"Fetroja","genericName":"CEFIDEROCOL","slug":"cefiderocol","indication":"Bacterial urinary infection","status":"marketed","revenue":300000000},{"name":"Keflex","genericName":"cefalexin","slug":"cefalexin","indication":"Acute otitis media","status":"marketed"},{"name":"Doribax","genericName":"DORIPENEM","slug":"doripenem","indication":"Abdominal abscess","status":"marketed"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":6,"colorKey":"neuroscience","drugs":[{"name":"Cuvposa","genericName":"GLYCOPYRRONIUM BROMIDE","slug":"glycopyrronium-bromide","indication":"Reduce chronic severe drooling","status":"marketed"},{"name":"Nonhormonal vaginal lubricant","genericName":"Nonhormonal vaginal lubricant","slug":"nonhormonal-vaginal-lubricant","indication":"Treatment of vaginal dryness and discomfort","status":"phase_3"},{"name":"Ospemifene (Dose 1)","genericName":"Ospemifene (Dose 1)","slug":"ospemifene-dose-1","indication":"Moderate to severe dyspareunia due to genitourinary syndrome of menopause (GSM)","status":"phase_3"},{"name":"Placebo to Baloxavir Marboxil","genericName":"Placebo to Baloxavir Marboxil","slug":"placebo-to-baloxavir-marboxil","indication":"Acute uncomplicated influenza (treatment)","status":"phase_3"},{"name":"Pravafen","genericName":"Pravafen","slug":"pravafen","indication":"Other","status":"phase_3"},{"name":"S-268019-b","genericName":"S-268019-b","slug":"s-268019-b","indication":"Functional dyspepsia","status":"phase_3"}]},{"name":"Dermatology","slug":"dermatology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"Ulesfia","genericName":"BENZYL ALCOHOL","slug":"benzyl-alcohol","indication":"Itching of skin","status":"marketed"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"infectious","drugs":[{"name":"S-217622","genericName":"S-217622","slug":"s-217622","indication":"Type 2 diabetes","status":"phase_3"}]}],"pipeline":[{"name":"Xocova","genericName":"ENSITRELVIR","slug":"ensitrelvir","phase":"marketed","mechanism":"Small molecule","indications":["Disease caused by Severe acute respiratory syndrome coronavirus 2"],"catalyst":""},{"name":"Fetroja","genericName":"CEFIDEROCOL","slug":"cefiderocol","phase":"marketed","mechanism":"Fetroja works by binding to penicillin-binding proteins on bacterial cell walls, inhibiting cell wall synthesis and ultimately leading to bacterial cell death.","indications":["Bacterial urinary infection","Escherichia coli urinary tract infection","Gram-Negative Bacterial Infections","Proteus urinary tract infection","Pseudomonas urinary tract infection"],"catalyst":""},{"name":"Keflex","genericName":"cefalexin","slug":"cefalexin","phase":"marketed","mechanism":"Solute carrier family 15 member 2","indications":["Acute otitis media","Bacterial urinary infection","Escherichia coli urinary tract infection","Haemophilus Influenzae Acute Otitis Media","Infection due to Staphylococcus aureus"],"catalyst":""},{"name":"Ulesfia","genericName":"BENZYL ALCOHOL","slug":"benzyl-alcohol","phase":"marketed","mechanism":"Small molecule","indications":["Itching of skin","Skin irritation"],"catalyst":""},{"name":"Cuvposa","genericName":"GLYCOPYRRONIUM BROMIDE","slug":"glycopyrronium-bromide","phase":"marketed","mechanism":"Cuvposa works by blocking the action of a chemical called acetylcholine, which stimulates the muscarinic receptors in the body.","indications":["Reduce chronic severe drooling"],"catalyst":""},{"name":"Doribax","genericName":"DORIPENEM","slug":"doripenem","phase":"marketed","mechanism":"Small molecule","indications":["Abdominal abscess","Cholecystitis","Complicated Urinary Tract Infections","Complicated appendicitis","Infectious disease of abdomen"],"catalyst":""},{"name":"Nonhormonal vaginal lubricant","genericName":"Nonhormonal vaginal lubricant","slug":"nonhormonal-vaginal-lubricant","phase":"phase_3","mechanism":"Nonhormonal vaginal lubricant works by providing moisture to the vagina to reduce friction and discomfort during sexual intercourse.","indications":["Treatment of vaginal dryness and discomfort"],"catalyst":""},{"name":"Oral Glycopyrrolate Liquid","genericName":"Oral Glycopyrrolate Liquid","slug":"oral-glycopyrrolate-liquid","phase":"phase_3","mechanism":"Glycopyrrolate is an anticholinergic medication that works by blocking the action of acetylcholine, a neurotransmitter that stimulates the parasympathetic nervous system, thereby reducing secretions and slowing the heart rate.","indications":["Chronic obstructive pulmonary disease (COPD)"],"catalyst":""},{"name":"Ospemifene (Dose 1)","genericName":"Ospemifene (Dose 1)","slug":"ospemifene-dose-1","phase":"phase_3","mechanism":"Ospemifene is a selective estrogen receptor modulator (SERM) that acts as an estrogen agonist in vaginal tissue to treat moderate to severe dyspareunia caused by genitourinary syndrome of menopause.","indications":["Moderate to severe dyspareunia due to genitourinary syndrome of menopause (GSM)"],"catalyst":""},{"name":"Placebo to Baloxavir Marboxil","genericName":"Placebo to Baloxavir Marboxil","slug":"placebo-to-baloxavir-marboxil","phase":"phase_3","mechanism":"Baloxavir marboxil is a cap-dependent endonuclease inhibitor that blocks influenza virus polymerase, preventing viral mRNA synthesis and replication.","indications":["Acute uncomplicated influenza (treatment)","Influenza prophylaxis (prevention)"],"catalyst":""},{"name":"Pravafen","genericName":"Pravafen","slug":"pravafen","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"S-217622","genericName":"S-217622","slug":"s-217622","phase":"phase_3","mechanism":"S-217622 is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"S-268019-b","genericName":"S-268019-b","slug":"s-268019-b","phase":"phase_3","mechanism":"S-268019-b is a selective serotonin 5-HT4 receptor partial agonist that enhances gastric motility and accelerates gastric emptying.","indications":["Functional dyspepsia","Gastroparesis"],"catalyst":""}],"recentEvents":[{"date":"2023-02-08","type":"regulatory","headline":"Shionogi's Ospemifene Receives Approval in Japan for Treatment of Moderate to Severe Dyspareunia","summary":"Shionogi & Co. announced that its osteoporosis treatment, Ospemifene, has received approval in Japan for the treatment of moderate to severe dyspareunia.","drugName":"Ospemifene","sentiment":"positive"},{"date":"2022-11-04","type":"earnings","headline":"Shionogi Reports Strong Q3 Earnings, Beats Analyst Estimates","summary":"Shionogi & Co. reported strong Q3 earnings, exceeding analyst estimates and driven by solid sales growth in key markets.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiVEFVX3lxTE1uNjVDSkFyaEJjRUdkWmRUcGdRUElmUmRQeE15dFk2a2I5R3RZUGRUYXkwamh6VUlzNlJ5REN6U3NPY3dhc0x1eG5QV1B3MmQ3Ql96SQ?oc=5","date":"2026-04-02","type":"pipeline","source":"Yahoo Finance UK","summary":"Shionogi & Co., Ltd. (4507.T) stock price, news, quote and history - Yahoo Finance UK","headline":"Shionogi & Co., Ltd. (4507.T) stock price, news, quote and history","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxQVVRjcEpRakdtdloxZjNfek05UXhMNVhqamx3bXppZHJ3bDAxdkEtWW9la2hCZG4xV1ZnZWprSGhLYmZVaW9fNDVCaXFNUjZ1dXB2bGJDaVlLd0Z1M3ItQjd5UWpoZ0tCR1dseTFuVjJHV1l1cVJUZkNrQ1dBTldCQzdpS04zQTF4MC1FN1J6OVZ2b0U3S3BtZEhfeENNMVBLRE0yUWdQVFdDcGJMODJLMEliSlUyRVE?oc=5","date":"2026-01-06","type":"pipeline","source":"AD HOC NEWS","summary":"Shionogi & Co Ltd Is Quietly Exploding – Is This ‘Boring’ Pharma Stock Your Next Power Play? - AD HOC NEWS","headline":"Shionogi & Co Ltd Is Quietly Exploding – Is This ‘Boring’ Pharma Stock Your Next Power Play?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizwFBVV95cUxQNWFFd1AtcEdBQTBjSEpIdHBNdmtJaXJ4QkJZWHZMcW9ZbXg4OWhMSVpjM0UwZ1NFR0tfRWt3Y2t2R1ZldlJkcXQxX1dsdjA0QVdNZ1JhRDNiMlE0ZF96ZWViN0o2VG1tMGZKMW5ORUdnazJOR1RTYk9mdjJONmJyajBzTnptdXVScWQtNnhrRVVmVzU4M2pXMGNtejRLaXdFS21MZURQQjhkcHlocmd5Mk5WZXJZRUZYdWxvX0cyeVNYaEh0aDk3ZGN4QldJVVE?oc=5","date":"2025-05-07","type":"deal","source":"Reuters","summary":"Drugmaker Shionogi to buy Japan Tobacco's unit Torii Pharmaceutical for $1 billion - Reuters","headline":"Drugmaker Shionogi to buy Japan Tobacco's unit Torii Pharmaceutical for $1 billion","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4AFBVV95cUxNQnpOS2hoZHNDeWcxUElmZHl2UW5xSHUxLVdYRDZROU85dE1tVVdpV3RDUV9sdnhLcW5XOEdpdEFIMS1KUm5kbUtNYkRZaE1VTjVOcFdKbjJfMU8yY1hyUXFPa2xBb1VFckJFNXZmRTRYd1IwWTEwQzJnODVGYkw4c0g4cDhRajQ1MzRUT1FqSXpzTkg1dGMtbWtZVlFMcmtVTjJINlJVTkNxMUwtTVFNNEx0YzFrLTZUaDItWk5LUDhoaDBfQWZ5dC1XSmpSZlF1cHd0WTktcmJ1REd2VmtCcQ?oc=5","date":"2024-05-13","type":"trial","source":"Reuters","summary":"Japan's Shionogi says COVID treatment did not meet endpoint in late-stage trial - Reuters","headline":"Japan's Shionogi says COVID treatment did not meet endpoint in late-stage trial","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3AFBVV95cUxNaVI3aC1jend1MVJiOEdid204dmRfQ1lUa0d0TklEVTdNWGpOQWREUmtlSExicGd2RXdUZXlYMUZGb1ZQQjRWem9GTUFISVdTaXh3d1ZNMzE5NWZEVXpieWVTZDRNVjBscU5FNjl4NTgtN0J1YmtvWHlHS2pfQUl5Y0RhRGRHZVl2UzhZaWoydHFiLUltUEtmOS01cVFaeDQ4dUExZUJ1R0twdnVoel9LYWMxX1QyWHN1dFNRaVVPcHJOcnVtM01zblh0RFU1Y1RBUHJvTy1udFo4X1VJ?oc=5","date":"2023-02-26","type":"regulatory","source":"Reuters","summary":"Shionogi sees COVID pill reaping $2 billion in annual sales upon U.S. approval - Reuters","headline":"Shionogi sees COVID pill reaping $2 billion in annual sales upon U.S. approval","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxNaVFsdW4wWktKeU1EY3dvRFM0LXdsenZ6bE5tRkU4cWVhX01nWEYwVUYzS3ZSblFoZVpydHdNNVhWVG8tREpoUnI3bXpjSlc2cGRBNnd3cXE3VDBhUmp6MllpOTM3RnMxbWgxYzBmVE53bWVGNkVsMWNxRmJ3Z1lOU01rSUZkNGt1dEQ1UjVSLTdia3JjVlBaQg?oc=5","date":"2022-04-24","type":"pipeline","source":"PharmaLive","summary":"Japan’s Shionogi says COVID-19 pill shows rapid clearance of virus - PharmaLive","headline":"Japan’s Shionogi says COVID-19 pill shows rapid clearance of virus","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiVEFVX3lxTE0xZVV1OHcyVzJlMjRWbmpsN3hfWnBQMkRSZVItLXY4QVdnaFhTb2RkS1FscWtrNWg2T0llekdoR09qSVNpd0V3RGxvRjNnYVFpVXRnNQ?oc=5","date":"2018-06-03","type":"pipeline","source":"Yahoo! Finance Canada","summary":"Nxera Pharma Co., Ltd. (4565.T) Stock Price, News, Quote & History - Yahoo! Finance Canada","headline":"Nxera Pharma Co., Ltd. (4565.T) Stock Price, News, Quote & History - Yahoo! Finance Canada","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiVEFVX3lxTFBFRmpSSWhpODZjdkxySU5LUFBybWNPRFhNTk10a0RIcklPZW9USDR4Y09mTlhtWk9oOXlYUm9Felk1R01UWElpT0xlZjZ0VHRoTlhEZA?oc=5","date":"2018-05-18","type":"pipeline","source":"Yahoo Finance Australia","summary":"Eisai Co., Ltd. (4523.T) stock price, news, quote and history - Yahoo Finance Australia","headline":"Eisai Co., Ltd. (4523.T) stock price, news, quote and history","sentiment":"neutral"}],"patents":[{"drugName":"Ospemifene","drugSlug":"ospemifene","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":1200000000}],"drugCount":13,"phaseCounts":{"marketed":6,"phase_3":7},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Astellas Pharma","Takeda Pharmaceutical","Eisai Co."],"therapeuticFocus":["Anti-Infectives","HIV","CNS Disorders"],"financials":{"source":"yahoo_finance","revenue":2770936895.5352,"revenuePeriod":"2025-03-31","revenueHistory":[{"period":"2025-03-31","value":2770936895.5352},{"period":"2024-03-31","value":2750787179.1833997},{"period":"2023-03-31","value":2697697386.8375998},{"period":"2022-03-31","value":2118900420.0532}],"grossProfit":2367392513.4874,"grossProfitHistory":[{"period":"2025-03-31","value":2367392513.4874},{"period":"2024-03-31","value":2386600181.6006},{"period":"2023-03-31","value":2304142509.6018},{"period":"2022-03-31","value":1768534344.9508}],"rdSpend":686696263.6968,"rdSpendHistory":[{"period":"2025-03-31","value":686696263.6968},{"period":"2024-03-31","value":648938464.4959999},{"period":"2023-03-31","value":647370491.5888},{"period":"2022-03-31","value":461515122.31439996}],"sgaSpend":644089128.9322,"operatingIncome":990124311.1256,"operatingIncomeHistory":[{"period":"2025-03-31","value":990124311.1256},{"period":"2024-03-31","value":969310735.2767999},{"period":"2023-03-31","value":942073528.4856},{"period":"2022-03-31","value":697444465.0768}],"netIncome":1077570413.059,"netIncomeHistory":[{"period":"2025-03-31","value":1077570413.059},{"period":"2024-03-31","value":1024430040.9419999},{"period":"2023-03-31","value":1169435922.501},{"period":"2022-03-31","value":721931396.809}],"eps":186.106667,"epsHistory":[{"period":"2024-03-31","value":186.106667},{"period":"2023-03-31","value":207.033333},{"period":"2022-03-31","value":126.21}],"cash":2369630668.363,"cashHistory":[{"period":"2025-03-31","value":2369630668.363},{"period":"2024-03-31","value":2264013783.626},{"period":"2023-03-31","value":1955059896.1936},{"period":"2022-03-31","value":1608563173.588}],"totalAssets":9707200141.5186,"totalLiabilities":1092858148.9042,"totalDebt":138348319.1748,"equity":8610725538.9736,"operatingCashflow":1235790259.8439999,"operatingCashflowHistory":[{"period":"2025-03-31","value":1235790259.8439999},{"period":"2024-03-31","value":975456177.4776},{"period":"2023-03-31","value":1124559020.5038},{"period":"2022-03-31","value":645322010.8551999}],"capex":-329419727.3542,"capexHistory":[{"period":"2025-03-31","value":-329419727.3542},{"period":"2024-03-31","value":-178717299.0638},{"period":"2023-03-31","value":-235113743.9518},{"period":"2022-03-31","value":-199562487.2696}],"freeCashflow":906370532.4898,"dividendsPaid":-307891712.23719996,"buybacks":-63224.714,"employees":0,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":null,"ebit":null,"ebitda":null,"period":"2025-06-30","revenue":null,"epsBasic":null,"netIncome":null,"rdExpense":null,"epsDiluted":46.25,"grossProfit":null,"operatingIncome":null}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":3076,"previousClose":2978,"fiftyTwoWeekHigh":3758,"fiftyTwoWeekLow":2173,"fiftyTwoWeekRange":"2173.0 - 3758.0","fiftyDayAverage":3328.88,"twoHundredDayAverage":2923.73,"beta":0.03,"enterpriseValue":16385231634.307533,"forwardPE":16.1,"priceToBook":1.73,"priceToSales":5.24,"enterpriseToRevenue":5.19,"enterpriseToEbitda":17.13,"pegRatio":0,"ebitda":956741663.7521527,"ebitdaMargin":30.3,"freeCashflow":-70802984.81501164,"operatingCashflow":1350302821.376983,"totalDebt":4327061623.243643,"debtToEquity":40.6,"currentRatio":1.58,"returnOnAssets":3.8,"returnOnEquity":13.5,"analystRating":"2.5 - Buy","recommendationKey":"buy","numberOfAnalysts":12,"targetMeanPrice":3483.33,"targetHighPrice":4000,"targetLowPrice":3000,"dividendRate":76,"payoutRatio":0.33,"fiveYearAvgDividendYield":2.09,"exDividendDate":1790640000,"insiderHeldPercent":4.8,"institutionHeldPercent":59.3,"sharesOutstanding":850975437,"floatShares":850975437,"sharesShort":0,"shortRatio":0,"shortPercentOfFloat":0,"epsTrailing":200.72,"epsForward":191.2,"revenuePerShare":587.23,"bookValue":1779.32,"officers":[{"age":66,"name":"Dr. Isao  Teshirogi Ph.D.","title":"CEO, President & Representative Director"},{"age":null,"name":"Takuji  Fujiwara","title":"Accounting & Finance Manager"},{"age":null,"name":"Mr. Takeshi  Shiota Ph.D.","title":"Corporate Officer and Senior VP of Corporate Quality Assurance, Ethics & Compliance Management Div."},{"age":null,"name":"Mr. Yoshimasa  Kyokawa","title":"Vice President of Corporate Communications & Secretary Office"},{"age":null,"name":"Yoshihiro  Furuya","title":"Vice President of General Marketing and Compliance Officer of Corporate GXP Compliance Office"},{"age":61,"name":"Dr. John Apeler  Keller Ph.D.","title":"Senior Exec. Officer, SVP of R&D Supervisory Unit and Pharma. Tech. Research Div. & Director"},{"age":null,"name":"Mr. Kazuhiro  Hatanaka","title":"Senior Executive Officer & Senior VP of Corporate Supervisory Unit"},{"age":null,"name":"Akira  Kato Ph.D.","title":"Senior Executive Officer & Senior VP of Supply Supervisory Unit"}],"industry":"Drug Manufacturers - Specialty & Generic","irWebsite":"http://www.shionogi.co.jp/ir_en/highlight/index.html","website":"https://www.shionogi.com","phone":"81 6 6202 2161"}}